05Y Stock Overview
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vivoryon Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.71 |
| 52 Week High | €19.50 |
| 52 Week Low | €0.40 |
| Beta | 1.28 |
| 1 Month Change | 35.77% |
| 3 Month Change | -91.62% |
| 1 Year Change | -96.32% |
| 3 Year Change | -95.06% |
| 5 Year Change | -84.03% |
| Change since IPO | -97.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| 05Y | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -9.9% | 0.8% | -0.5% |
| 1Y | -96.3% | -21.0% | 2.5% |
Return vs Industry: 05Y underperformed the German Biotechs industry which returned -21% over the past year.
Return vs Market: 05Y underperformed the German Market which returned 2.5% over the past year.
Price Volatility
| 05Y volatility | |
|---|---|
| 05Y Average Weekly Movement | 33.0% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 05Y's share price has been volatile over the past 3 months.
Volatility Over Time: 05Y's weekly volatility has increased from 18% to 33% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 15 | Frank Weber | www.vivoryon.com |
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease.
Vivoryon Therapeutics N.V. Fundamentals Summary
| 05Y fundamental statistics | |
|---|---|
| Market cap | €18.51m |
| Earnings (TTM) | -€28.34m |
| Revenue (TTM) | n/a |
-5.1x
P/S Ratio-0.7x
P/E RatioIs 05Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 05Y income statement (TTM) | |
|---|---|
| Revenue | -€3.62m |
| Cost of Revenue | -€525.00k |
| Gross Profit | -€3.09m |
| Other Expenses | €25.25m |
| Earnings | -€28.34m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.09 |
| Gross Margin | 85.50% |
| Net Profit Margin | 782.93% |
| Debt/Equity Ratio | 0% |
How did 05Y perform over the long term?
See historical performance and comparison